https://www.live-feeds.com/feed/insilico-s-co-ceo-hopes-we-might-have-a-chance-to-stop-biological-agingContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/insilico-s-co-ceo-hopes-we-might-have-a-chance-to-stop-biological-aginghttps://www.live-feeds.com/feed/insilico-s-co-ceo-hopes-we-might-have-a-chance-to-stop-biological-aging#u64156Thu, 10 Sep 2026 17:58:37 +0000Insilico Medicine began dosing the first patient on September 9, 2026, for the GENESIS-IPF-3 trial, the first Phase III study of a generative AI-driven drug. While the candidate targets lung disease, early data suggests it may slow or reverse biological aging. The company's co-CEO believes this technology provides a chance to stop biological aging. Researchers are utilizing proteomic aging clocks in Phase 2a trials to assess these geroprotective effects simultaneously with primary disease treatment.Why it mattersGenerative AI is being used to accelerate drug discovery by designing molecul